2024 EHA abstract PB1112: COMBINATION TREATMENT WITH NOVEL BCL-2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MCL 声明 本资讯...
在此次ASCO年会上展示的该临床研究核心要点如下：Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia.新型Bcl-2抑制剂APG-2575(Lisaftoclax)联合阿扎胞苷治疗初治或复发/难治急性髓...
8. Nan Hu,et al. Abstract 3077: Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. Cancer Res 15 August 2020; 80 (16_S...
英文名称:Bcl-2 Inhibitor 分子式:C42H45ClN6O5S2 纯度:96.4% 产地:北京 品牌:百奥莱博 包装规格:10mM×0.2ml|5mg|25mg 货号:YT921 CAS编号:852808-04-9 本品是一种BH3模拟抑制剂,作用于Bcl-xL、Bcl-2和Bcl-w,无细胞试验中EC50分别为78.7nM、30.3nM和197.8nM,但对Mcl-1、Bcl-B及Bfl-1没有抑制作用...
英文名称: TW-37/Bcl-2 Inhibitor CAS: 877877-35-5 纯度: Purity≥98% 单位: 瓶 产品仅用于科研储存条件:避光、干燥阴凉处封闭贮存,严禁与有毒、有害物品混放、混运。本品为非危险 产品可按一般化学品运输,轻搬动轻放,防止日晒、雨淋!受热、受潮、受光后易丧失活力,保存期短,因此贮存和运输条件比较苛刻。
2023年12月7日,中山大学肿瘤防治中心赵洪云教授、杨大俊研究员、张力教授研究团队在Cellular & Molecular Immunology杂志发表了题为“The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation”的研究成果(...
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs) ...
Venetoclax基础信息 中文名：维奈妥拉 英文名：ABT-199 ，Venetoclax， Bcl-2 inhibitor CAS号：1257044-40-8 结构式：O=C(NS(=O)(C1=CC=C(NCC2CCOCC2)C([N+]([O-])=O)=C1)=O)C3=CC=C(N4CCN(CC5=C(C6=CC=C(Cl)C=C6)CC(C)(C)CC5)CC4)C=C3OC7=CN=C(NC=C8)C8=C7 分子式：C45H50...
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma(2020); Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives(2021); Therapeutic development and current uses of BCL-2 inhibition(2020); ...
APG-2575在EHA 2022上展示的核心要点如下：Preliminary Results of a Phase 1 Study of Novel Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients (pts) with Relapsed or Refractory (r/r) Non-Hodgkin Lymphomas (NHLs)新型Bcl-2抑制剂lisaftoclax (APG-2575)治疗中国复发/难治性(r/r)非霍奇金...